Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.50

Atossa Therapeutics (NASDAQ:ATOS) had its target price lifted by Ascendiant Capital Markets from $6.25 to $6.50 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would suggest a potential upside of 333.33% from the company’s previous close.

Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Atossa Therapeutics in a research report on Monday, August 12th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th.

Atossa Therapeutics Trading Down 1.3 %

Shares of ATOS stock opened at $1.50 on Wednesday. The firm has a market capitalization of $188.64 million, a P/E ratio of -6.25 and a beta of 1.19. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31. The firm’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities research analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Institutional Trading of Atossa Therapeutics

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Atossa Therapeutics during the second quarter worth $29,000. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the 1st quarter worth about $72,000. Virtu Financial LLC bought a new stake in shares of Atossa Therapeutics in the 1st quarter worth about $151,000. Rhumbline Advisers acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $161,000. Finally, Bank of New York Mellon Corp lifted its holdings in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.